Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Assembly committee hears industry leaders describe California’s ‘medtech’ edge and policy needs
Summary
Industry witnesses told an Assembly select committee that medical technology differs from biopharma, relies on manufacturing clusters and mid‑skill workers, and needs state policy attention on workforce training, supply chains and translational funding to keep production and jobs in California.
California’s Assembly Select Committee on Biotechnology and Medical Technology heard industry representatives on Feb. 18 explain how medical technology — or medtech — operates differently from biopharma and why that difference matters for state policy. Chair Ward convened the hearing in Room 127 of the State Capitol with two panels of industry witnesses.
Medtech, Gregory Theil, director of the Biomedical Manufacturing Network, told the committee, is ‘‘hardware’’ in many forms — from implanted devices such as pacemakers and stents to surgical robots and wearables — and typically follows an incremental development path with much shorter regulatory timelines than many drugs. ‘‘When you…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
